Outcomes of dexmedetomidine as adjuvant drug in patients undergoing videolaparoscopic cholecystectomy: A randomized and prospective clinical trial
International Journal of Immunopathology and Pharmacology · 2023
DOI: 10.1177/03946320231196977 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Immunopathology and Pharmacology, 2023. Verfasst von Gustavo Nascimento Silva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Gaffreé e Guinle University Hospital, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Dexmedetomidine, Cholecystectomy, Laparoscopic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universidade Federal do Estado do Rio de Janeiro.
Abstract (Originalsprache)
Objective
The repercussions of ischemia-reperfusion and inflammatory response to surgical injury may compromise the return of physiologic processes in video-laparoscopic surgeries. Dexmedetomidine, as an adjuvant drug in general anesthesia, alters the neuroinflammatory reaction, provides better clinical outcomes in the perioperative period, and may reduce the excessive use of chronic medication in patients with a history of addiction. This study evaluated the immunomodulatory potential of dexmedetomidine on perioperative organ function in video-laparoscopic cholecystectomy patients.
Methods
There were two groups: Sevoflurane and Dexmedetomidine A (26 patients) vs. Sevoflurane and Saline 0.9% B (26 patients). Three blood samples were collected three times: 1) before surgery, 2) 4–6h after surgery, and 3) 24h postoperatively. Inflammatory and endocrine mediators were protocolized for analysis. Finally, hemodynamic outcomes, quality upon awakening, pain, postoperative nausea and vomiting, and opioid use were compared between groups.
Results
We have demonstrated a reduction of Interleukin 6 six hours after surgery in group A: 34.10 (IQR 13.88–56.15) vs. 65.79 (IQR 23.13–104.97; p = 0.0425) in group B. Systolic blood pressure, diastolic blood pressure, and mean arterial pressure was attenuated in group A in their measurement intervals ( p < 0.0001). There was a lower incidence of pain and opioid consumption in the first postoperative hour favoring this group ( p < 0.0001). We noticed better quality upon awakening after the intervention when comparing the values of peripheral oxygen saturation and respiratory rate.
Conclusions
Dexmedetomidine provided anti-inflammatory benefits and contributed to postoperative analgesia without the depressive side effects on the respiratory and cardiovascular systems commonly observed with opioids. Trial Registration Immunomodulatory Effect of Dexmedetomidine as an Adjuvant Drug in Laparoscopic Cholecystectomies, NCT05489900, Registered 5 August 2022—Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT05489900?term=NCT05489900&draw=2&rank=1
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Gaffreé e Guinle University Hospital, Federal University of the State of Rio de Janeiro, Rio de Janeiro, Brazil.
- Department of Anesthesiology, University Hospital of Juiz de Fora Federal University, Juiz de Fora, Brazil.
- Department of General and Specialized Surgery, Gaffrée e Guinle University Hospital, Federal University of the State of Rio de Janeiro (UNIRIO), Rio de Janeiro, Brazil.
- Department of Surgery and Anesthesia, Federal University of São Paulo (UNIFESP), São Paulo, Brazil.
- Medicine School, Fluminense Federal University, Niterói, Brazil.
- Center for Advanced Spine Care of Southern Arizona, Surgical Institute of Tucson, Tucson, AZ, USA.
ORCID-Profile: Gustavo Nascimento Silva
Förderung
- Universidade Federal do Estado do Rio de Janeiro
Zitieren
APA
Silva, G. N., Brandão, V. G., Fiorelli, R., Perez, M. V., Mello, C. R., Negrini, D., Levandrowski, K. U., Martinelli, R. B., & Reis, T. P. D. A. D. (2023). Outcomes of dexmedetomidine as adjuvant drug in patients undergoing videolaparoscopic cholecystectomy: A randomized and prospective clinical trial. International Journal of Immunopathology and Pharmacology. https://doi.org/10.1177/03946320231196977
Vancouver
Silva GN, Brandão VG, Fiorelli R, Perez MV, Mello CR, Negrini D, et al. Outcomes of dexmedetomidine as adjuvant drug in patients undergoing videolaparoscopic cholecystectomy: A randomized and prospective clinical trial. International Journal of Immunopathology and Pharmacology. 2023. doi:10.1177/03946320231196977
BibTeX
@article{Silva2023,
author = {Silva, Gustavo Nascimento and Brandão, Virna Guedes and Fiorelli, Rossano and Perez, Marcelo Vaz and Mello, Carolina Ribeiro and Negrini, Daniel and Levandrowski, Kai-Uwe and Martinelli, Rafael Bof and Reis, Tatiana Pereira do Amaral Dos},
title = {Outcomes of dexmedetomidine as adjuvant drug in patients undergoing videolaparoscopic cholecystectomy: A randomized and prospective clinical trial},
journal = {International Journal of Immunopathology and Pharmacology},
year = {2023},
doi = {10.1177/03946320231196977}
}
EUVIMED